Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
46
SLNO Quote, Financials, Valuation and Earnings
Last price:
$47.77
Seasonality move
:
15.77%
Day range:
$47.46 - $49.33
52-week range:
$41.50 - $90.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.70x
P/B ratio:
5.19x
Volume:
2.3M
Avg. volume:
1.7M
1-year change:
5.86%
Market cap:
$2.6B
Revenue:
--
EPS (TTM):
-$1.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$90.2M | $0.08 | -- | -- | $113.54 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.12 | 12.96% | -83.59% | $29.79 |
|
AGL
Agilon Health, Inc.
|
$1.6B | -$0.11 | -4.03% | -6.74% | $0.97 |
|
GERN
Geron Corp.
|
$53.8M | -$0.03 | 7.03% | -8.38% | $3.60 |
|
RCEL
AVITA Medical, Inc.
|
$19.5M | -$0.29 | -5.46% | -22.14% | $7.92 |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$47.85 | $113.54 | $2.6B | -- | $0.00 | 0% | 23.70x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.16 | $29.79 | $4.6B | 17.48x | $0.00 | 0% | 4.37x |
|
AGL
Agilon Health, Inc.
|
$0.73 | $0.97 | $304.5M | -- | $0.00 | 0% | 0.05x |
|
GERN
Geron Corp.
|
$1.33 | $3.60 | $849M | -- | $0.00 | 0% | 4.83x |
|
RCEL
AVITA Medical, Inc.
|
$3.46 | $7.92 | $105.5M | -- | $0.00 | 0% | 1.28x |
|
SAVA
Cassava Sciences, Inc.
|
$2.18 | $8.00 | $105.1M | -- | $0.00 | 0% | 2.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
9.62% | -1.583 | 1.45% | 15.77x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
AGL
Agilon Health, Inc.
|
10.82% | -3.454 | 8.69% | 0.25x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
RCEL
AVITA Medical, Inc.
|
117.49% | -1.939 | 28.73% | 0.52x |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.880 | -- | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$64.9M | $22.7M | -23.2% | -26.56% | 34.41% | $43.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
AGL
Agilon Health, Inc.
|
-$75.1M | -$127.2M | -65.38% | -71.4% | -8.86% | -$34.7M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
RCEL
AVITA Medical, Inc.
|
$13.9M | -$9.2M | -111.55% | -1112.54% | -53.65% | -$6.5M |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
Soleno Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SLNO or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 25.76%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SLNO or ACAD?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 137.28%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 9.68%. Given that Soleno Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SLNO or ACAD More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock SLNO or ACAD?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ACAD?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Soleno Therapeutics, Inc.'s net income of $26M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 23.70x versus 4.37x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.23.70x -- $66M $26M ACADACADIA Pharmaceuticals, Inc.4.37x 17.48x $278.6M $71.8M
-
Which has Higher Returns SLNO or AGL?
Agilon Health, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -7.68%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Agilon Health, Inc.'s return on equity of -71.4%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M AGLAgilon Health, Inc.-5.23% -$0.27 $343.2M -
What do Analysts Say About SLNO or AGL?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 137.28%. On the other hand Agilon Health, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 31.38%. Given that Soleno Therapeutics, Inc. has higher upside potential than Agilon Health, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Agilon Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 AGLAgilon Health, Inc.2 13 0 -
Is SLNO or AGL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Agilon Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or AGL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilon Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Agilon Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or AGL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than Agilon Health, Inc. quarterly revenues of $1.4B. Soleno Therapeutics, Inc.'s net income of $26M is higher than Agilon Health, Inc.'s net income of -$110.2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Agilon Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 23.70x versus 0.05x for Agilon Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.23.70x -- $66M $26M AGLAgilon Health, Inc.0.05x -- $1.4B -$110.2M
-
Which has Higher Returns SLNO or GERN?
Geron Corp. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -39.02%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About SLNO or GERN?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 137.28%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 170.68%. Given that Geron Corp. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Geron Corp. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 GERNGeron Corp.3 1 1 -
Is SLNO or GERN More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock SLNO or GERN?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or GERN?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Geron Corp. quarterly revenues of $47.2M. Soleno Therapeutics, Inc.'s net income of $26M is higher than Geron Corp.'s net income of -$18.4M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 23.70x versus 4.83x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.23.70x -- $66M $26M GERNGeron Corp.4.83x -- $47.2M -$18.4M
-
Which has Higher Returns SLNO or RCEL?
AVITA Medical, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -77.29%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat AVITA Medical, Inc.'s return on equity of -1112.54%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M RCELAVITA Medical, Inc.81.32% -$0.46 $38.1M -
What do Analysts Say About SLNO or RCEL?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 137.28%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $7.92 which suggests that it could grow by 127.9%. Given that Soleno Therapeutics, Inc. has higher upside potential than AVITA Medical, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than AVITA Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 RCELAVITA Medical, Inc.3 2 1 -
Is SLNO or RCEL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.807%.
-
Which is a Better Dividend Stock SLNO or RCEL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or RCEL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than AVITA Medical, Inc. quarterly revenues of $17.1M. Soleno Therapeutics, Inc.'s net income of $26M is higher than AVITA Medical, Inc.'s net income of -$13.2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 23.70x versus 1.28x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.23.70x -- $66M $26M RCELAVITA Medical, Inc.1.28x -- $17.1M -$13.2M
-
Which has Higher Returns SLNO or SAVA?
Cassava Sciences, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of --. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About SLNO or SAVA?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 137.28%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 267.82%. Given that Cassava Sciences, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 SAVACassava Sciences, Inc.1 0 0 -
Is SLNO or SAVA More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.081, suggesting its less volatile than the S&P 500 by 208.123%.
-
Which is a Better Dividend Stock SLNO or SAVA?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or SAVA?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Soleno Therapeutics, Inc.'s net income of $26M is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 23.70x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.23.70x -- $66M $26M SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
